Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of TD-1473 Formulations in Healthy Subjects
NCT04587713Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of izencitinib in ulcerative colitis (UC) and Crohn's disease (9 arms), sponsored by Theravance Biopharma, Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Measurable Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Oct 2020; status: completed.
02
Drugs
izencitinib
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04587713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587713.